Physician profile
Amy Castillo
NPI 1477783736
$3,706.44
in general payments reported to CMS, 2019-2025
21 companies · $783 in 2025
The $783 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $1,289 · 2024: $1,477 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506 · Education: $43.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.28 |
| Education | $43.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,322.63 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,128.74 | 2022-2025 | Descovy, Biktarvy, Yeztugo |
| Merck Sharp & Dohme LLC | $414.78 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Exact Sciences Corporation | $227.17 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $93.11 | 2023-2024 | |
| Janssen Biotech, INC. | $93.06 | 2022-2023 | Symtuza |
| Emd Serono, INC. | $69.44 | 2022-2025 | |
| Pfizer INC. | $68.64 | 2023-2025 | |
| Organon LLC | $43.71 | 2023 | Nexplanon |
| Napo Pharmaceuticals INC | $37.22 | 2025 | Mytesi |
| Coopersurgical, INC. | $36.88 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Alkermes, INC. | $23.91 | 2023 | Vivitrol |
| Glaxosmithkline, LLC. | $22.79 | 2025 | Shingrix |
| Biogen, INC. | $19.02 | 2025 | Zurzuvae |
| Xeris Pharmaceuticals, INC. | $17.96 | 2023 | Gvoke Hypopen |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 | |
| Antares Pharma, INC. | $15.93 | 2024 | Xyosted |
| Lilly USA, LLC | $14.12 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $13.57 | 2024 | Farxiga |
| Neurocrine Biosciences, INC. | $13.43 | 2024 | Ingrezza |
| Theratechnologies INC. | $13.35 | 2023 | Trogarzo, Egrifta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.